Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pictures Equal A Thousand Words In Previously Unreleased “Untitled” Letters

This article was originally published in The Gray Sheet

Executive Summary

Device manufacturers should exercise caution when including images in promotional materials to prevent making claims beyond the approved indications, recently publicized letters sent by FDA to companies suggest

You may also be interested in...



FDA Policy Power Challenged In House Questions On Untitled Letters

House lawmakers want to know if FDA is aware of consequences of publishing letters during stock trading hours.

FDA Surveillance Of Ads, Promotional Materials To Increase

FDA says it is stepping up surveillance of advertising and promotional materials for medical devices

FDA Surveillance Of Ads, Promotional Materials To Increase

FDA says it is stepping up surveillance of advertising and promotional materials for medical devices

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023268

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel